Conroy Sean, Kindon Nicholas, Kellam Barrie, Stocks Michael J
Centre for Biomolecular Sciences, University of Nottingham , University Park, Nottingham NG7 2RD, U.K.
J Med Chem. 2016 Nov 23;59(22):9981-10005. doi: 10.1021/acs.jmedchem.5b01972. Epub 2016 Aug 1.
P2Y receptors are expressed in virtually all cells and tissue types and mediate an astonishing array of biological functions, including platelet aggregation, smooth muscle cell proliferation, and immune regulation. The P2Y receptors belong to the G protein-coupled receptor superfamily and are composed of eight members encoded by distinct genes that can be subdivided into two groups on the basis of their coupling to specific G-proteins. Extensive research has been undertaken to find modulators of P2Y receptors, although to date only a limited number of small-molecule P2Y receptor antagonists have been approved by drug/medicines agencies. This Perspective reviews the known P2Y receptor antagonists, highlighting oral drug-like receptor antagonists, and considers future opportunities for the development of small molecules for clinical evaluation.
P2Y受体几乎在所有细胞和组织类型中均有表达,并介导一系列惊人的生物学功能,包括血小板聚集、平滑肌细胞增殖和免疫调节。P2Y受体属于G蛋白偶联受体超家族,由八个成员组成,这些成员由不同的基因编码,根据它们与特定G蛋白的偶联可分为两组。尽管迄今为止仅有少数小分子P2Y受体拮抗剂获得药品监管机构的批准,但人们已开展了广泛研究以寻找P2Y受体的调节剂。本综述回顾了已知的P2Y受体拮抗剂,重点介绍了口服类药物受体拮抗剂,并探讨了开发用于临床评估的小分子药物的未来机遇。